Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics Inc. is poised for substantial revenue growth driven by its expanding portfolio of treatments addressing severe disorders, with projected risk-adjusted revenues from hypercortisolism reaching $698 million by 2030 and revenues related to Cushing’s syndrome potentially rising to nearly $824 million in the same timeframe. The company reported a record increase in prescribers and patients for its lead product, Korlym, indicative of growing physician awareness and screening efforts. Furthermore, successful regulatory outcomes for the selective cortisol modulator, relacorilant, could open additional revenue streams, particularly in resistant hypertension and difficult-to-control diabetes markets, further strengthening Corcept's financial outlook.

Corcept Therapeutics Inc faces significant operational challenges that are anticipated to lead to lower revenue in 2025, particularly as demand for their drug requires resolution. Furthermore, there is a noted lack of prescriber awareness and appreciation of Korlym, with 70% of surveyed physicians indicating limited awareness or data as obstacles to adoption, compounded by misconceptions regarding the prevalence of hypercortisolism. Additionally, barriers such as drug costs and safety concerns contribute to the unfavorable environment for Korlym’s market penetration and overall growth prospects.